Aurinia Pharmaceuticals (AUPH) Interest Expenses (2023 - 2026)

Aurinia Pharmaceuticals has reported Interest Expenses for 4 years, with the latest figure at $1.0 million in Q1 2026.

• For the quarter ending Q1 2026, Interest Expenses fell 5.15% year-over-year to $1.0 million; the trailing twelve-month figure through Mar 2026 stood at $4.3 million (down 7.45% YoY), and the FY2025 full-year result was $4.3 million, down 10.44% from the prior year.
• Interest Expenses for Q1 2026 stood at $1.0 million, down from $1.0 million in the prior quarter.
• The five-year high for Interest Expenses was $1.4 million in Q3 2023, with the low at $65000.0 in Q2 2023.
• Historically, Interest Expenses has averaged $1.1 million across 4 years, with a median of $1.1 million in 2024.
• Annual changes were most pronounced in 2024 — Interest Expenses surged 1743.08% — and 2025, when it dropped 16.84%.
• Aurinia Pharmaceuticals' Interest Expenses stood at $1.3 million in 2023, then fell by 12.52% to $1.1 million in 2024, then dropped by 8.64% to $1.0 million in 2025, then slipped by 3.34% to $1.0 million in 2026.
• The last three Interest Expenses figures came in at $1.0 million (Q1 2026), $1.0 million (Q4 2025), and $1.1 million (Q3 2025), per Business Quant data.